Your browser is no longer supported. Please, upgrade your browser.
Settings
MTP Midatech Pharma Plc daily Stock Chart
MTP [NASD]
Midatech Pharma Plc
Index- P/E- EPS (ttm)-0.83 Insider Own53.04% Shs Outstand48.72M Perf Week19.28%
Market Cap31.38M Forward P/E- EPS next Y- Insider Trans- Shs Float26.95M Perf Month-7.58%
Income- PEG- EPS next Q- Inst Own- Short Float0.18% Perf Quarter-11.59%
Sales10.04M P/S3.12 EPS this Y- Inst Trans- Short Ratio0.75 Perf Half Y-34.28%
Book/sh1.50 P/B0.43 EPS next Y- ROA- Target Price- Perf Year-73.92%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.45 - 2.65 Perf YTD-23.09%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-75.69% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low43.13% ATR0.08
Employees85 Current Ratio- Sales Q/Q4.60% Oper. Margin- RSI (14)52.53 Volatility18.60% 13.45%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.26 Prev Close0.58
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume63.98K Price0.64
Recom- SMA206.24% SMA50-3.85% SMA200-30.83% Volume16,536 Change10.30%
Jul-25-18 07:00AM  Midatech Pharma PLC: Trading Update GlobeNewswire -5.78%
Jul-23-18 09:23AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:11AM  Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology Market in United States GlobeNewswire
Jun-08-18 02:00AM  Midatech Pharma US enrols first patient in Gelclair trial in stem cell transplant GlobeNewswire +9.88%
May-29-18 02:51PM  Tuesday's Market Sell-Off: The 52 Week Highs and Lows TheStreet.com
May-25-18 07:00AM  Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer GlobeNewswire
May-03-18 08:20AM  Todays Research Reports on Stocks to Watch: Midatech Pharma and Eleven Biotherapeutics ACCESSWIRE -14.19%
Apr-27-18 09:45AM  MTP: Midatech Targeting $2 Billion Market Opportunity with MTD201 Zacks Small Cap Research
Mar-23-18 03:32AM  Where Münchener Tierpark Hellabrunn AGs (MUN:MTP) Earnings Growth Stands Against Its Industry Simply Wall St.
Mar-15-18 08:01AM  Midatech announces changes in Senior Management Team GlobeNewswire +28.55%
Mar-07-18 10:15AM  MTP: Lead Candidates Set to Enter the Clinic; U.S. Product Sales Up ~30% in 2017 Zacks Small Cap Research
Feb-28-18 07:00AM  Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency GlobeNewswire
Feb-14-18 07:00AM  Midatech Pharma Plc: Trading update GlobeNewswire
Jan-16-18 07:01AM  Midatech and UCSF receive IND approval for DIPG treatment MTX110 GlobeNewswire
Jan-12-18 12:00PM  MTP: Receives Approval to Initiate First In Human Trial of Q-Octreotide (MTD201); Four Year Loan Agreement with MidCap Financial Zacks Small Cap Research
Nov-27-17 03:00PM  Initiating Coverage of Midatech Pharma (MTP); Novel Nanotechnology Platforms Focused on Oncology and Other Therapeutic Areas Zacks Small Cap Research -5.88%
Oct-27-17 01:59PM  Is Midatech Pharma Plc (AIM:MTPH) Undervalued? Simply Wall St. -6.08%
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.